Mark Lappe News Today

The deal gives Sanofi access to Inhibrx's therapy for a genetic disorder that raises a patient's risk for lung cancer and other disease

French healthcare company Sanofi has agreed to buy the drug development project INBRX-101 from its parent company Inhibrx Inc for around $2.2 billion, the companies said on Tuesday. As part of this deal, Inhibrx shareholders will get $30 per share in cash, one contingent value right (CVR) equal to $5 and 0.25 shares in New Inhibrx, a new publicly traded company. Following the closing of the deal, New Inhibrx will continue to operate under the "Inhibrx" name and will be led by Mark La...

Inhibrx, Inc. shareholders will receive per share consideration of $30 per share in cash, a CVR equal to $5, plus 0.25 shares in New Inhibrx, a new publicly traded company that retains all non-101...

The acquisition is the latest in a string of small- and mid-sized deals as Sanofi looks to double down on innovative medicines and reduce its reliance on the blockbuster asthma medicine Dupixent.

Sanofi: The two companies said in a joint statement on Tuesday that Inhibrx shareholders will get $30 per share in cash, one contingent value right (CVR) equal to $5, and 0.25 shares in New Inhibrx, a new publicly traded company that holds the takeover targets assets that are not related to INBRX-101.

Inhibrx announced an agreement with Sanofi on Tuesday, under which Sanofi subsidiary Aventis will acquire all assets and liabilities associated with INBRX-101, a recombinant alpha-1 antitrypsin (AAT) augmentation therapy currently being trialled for alpha-1 antitrypsin deficiency (AATD) treatment.

Sanofi's strategic acquisition of Inhibrx's INBRX-101, a alpha-1 antitrypsin therapy in a registrational trial. Learn about the $2.2B merger details and Inhibrx Biosciences' spin-off. Closing expected in Q2 2024.

Sanofi is buying Inhibrx in a $1.7 billion deal as the French pharmaceutical giant expands its pipeline of drugs that can treat rare diseases.

Aventis Inc. entered into a definitive agreement to acquire Inhibrx, Inc. for $1.4 billion on January 22, 2024. Immediately prior to the closing of the merger, all non-101 assets and liabilities,...

BioPharma